None listed
Conditions
Interventions
None listed
Sponsors
Martin Sinclair BB Corp
Eligibility
Inclusion criteria
Inclusion criteria: 1. Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures. 2. Age 18-75 years (both inclusive) at the time of signing ICF. 3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization). 4. Patients with uncomplicated respiratory tract viral infection 5. For female patients: evidence of post-menopause or for Pre-menopause patients, negative pretreatment serum or urine pregnancy test. 6. Eligible patients of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment. 7. Not participating in any other interventional drug clinical studies before completion of the present study 8. Controlled diabetic patients with HbA1C limit 9. Hypertension Patients up till Hypertension Stage 2 shall be included in the study (Systolic blood pressure at least 140mm Hg and Diastolic blood pressure at least 90 mm Hg) 10. Time interval between symptoms onset and randomization to no more than 7 days. 11. Pyrexia (axillary > 98.6°F or frontal >99.5°F); or/and any of the following symptoms: • Cough • Sore throat • Headache • Nasal congestion • Body aches and pains • Fatigue 12. Patients with Loss of smell and Taste.
Exclusion criteria
Exclusion criteria: COVID - 19 patients with history or significant presence of the following will be excluded from participation/enrollment in the study trial: 1. Severe infection, defined as oxygen saturation (SPO2) 2. Requires ICU care for management of ongoing clinical status. 3. Participation in this study will not be in the best interest of the patient, or any other circumstances that prevent the patient from participating in the study safely. 4. Inability to intake or tolerate oral medications like refractory nausea, vomiting, or gastrointestinal disorders, or having undergone extensive bowel resection which may affect adequate absorption of the drug. 5. Known severe renal impairment [creatinine clearance (CrCl) 1.5Ã?ULN. 6. patient has a serious chronic disease (e.g., human immunodeficiency virus (HIV), cancer requiring chemotherapy within the preceding 6 months, unstable cardiac, pulmonary (Asthma, chronic obstructive lung disease), neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days. 7. Psychiatric disease that is not well controlled (controlled defined as stable on a regimen for more than one year). 8. Known severely reduced LV function (Ejection fraction 9. Severe liver disease: underlying liver cirrhosis or Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN. 10. Gout/history of gout or hyperuricemia (above the ULN). 11. Pregnant or lactating women. 12. Having participated in any other interventional drug clinical study within 30 days prior to first dose of study drug. 13. Clinical prognostic non-survival, palliative care, and have no response to supportive treatment within three hours of admission. 14. Patients with diabetes having HbA1C limit > 7.0 15. Patients with Hypertensive crisis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with Microbiological cure at Day 02. Timepoint: Study enrolment visit (Day 00) On Therapy visit (Day 01) Evaluation visit (Day 02) | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of treatment-emergent adverse event at Day 02.Timepoint: Study enrolment visit (Day 00) On Therapy visit (Day 01) Evaluation visit (Day 02) | — |
Countries
India
Contacts
Public ContactDr Reenee Rajan
KMS Hospital
Outcome results
None listed